研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

阿巴西普用于治疗类风湿性关节炎费尔蒂综合征的用途。

The Use of Abatacept for the Treatment of Felty Syndrome in Rheumatoid Arthritis.

发表日期:2023 Sep
作者: Rishika V Chin, Sheila Serin, Ahmed Khan, Keneisha Smith, Suresh Kumar
来源: Arthritis & Rheumatology

摘要:

费尔蒂综合征的特征是类风湿性关节炎、中性粒细胞减少和脾肿大三联征,通常发生在血清阳性类风湿性关节炎患者中。我们报告一例81岁男性,有22年类风湿性关节炎病史,出现全血细胞减少和中性粒细胞减少一个月。腹部超声检查显示脾肿大。骨髓活检排除了大颗粒淋巴细胞白血病,因此诊断为费尔蒂综合征。他接受了最大耐受剂量的甲氨蝶呤(每周 15 毫克)治疗两个月,中性粒细胞绝对计数没有改善。患者每四周静脉注射 1000 mg 阿巴西普,血红蛋白、白细胞和血小板计数以及绝对中性粒细胞计数从 0.2 K/μl 改善至 2.4 K/μl。版权所有 © 2023,Chin 等人。
Felty syndrome is characterized by a triad of rheumatoid arthritis, neutropenia, and splenomegaly that typically occurs in patients with seropositive rheumatoid arthritis. We report a case of an 81-year-old man with a 22-year history of rheumatoid arthritis who developed pancytopenia and neutropenia for one month. An abdominal ultrasound revealed splenomegaly. A bone marrow biopsy excluded large granular lymphocytic leukemia, thus Felty Syndrome was diagnosed. He was treated with a maximum tolerated dose of methotrexate (15 mg once a week) for two months with no improvement in absolute neutrophil count. The patient was given abatacept 1000 mg intravenously every four weeks with improvement in hemoglobin, leukocyte, and platelet counts and absolute neutrophil counts from 0.2 to 2.4 K/µl.Copyright © 2023, Chin et al.